Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOXM1 | Q08050 | 2/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | REN | P00797 | 5/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5555630 | 0.99 | FOXM1 (0.56) | FOXM1HRH3KCNH2RENCYP2C9 | |
| SCHEMBL5249481 | 0.86 | HRH3 (0.60) | FOXM1HRH3KCNH2KDM4EKMT2A | |
| SCHEMBL10798982 | 0.86 | HRH3 (0.60) | HRH3KCNH2CYP2C9KMT2ASMN1; SMN2 | |
| SCHEMBL6654521 | 0.85 | HRH3 (0.58) | FOXM1HRH3KCNH2CYP2C9SMN1; SMN2 | |
| SCHEMBL7668635 | 0.82 | HRH3 (0.56) | FOXM1HRH3KCNH2KDM4EKMT2A | |
| SCHEMBL25730691 | 0.81 | HRH3 (0.45) | FOXM1HRH3KCNH2KDM4EKMT2A | |
| SCHEMBL21615694 | 0.80 | HRH3 (0.60) | FOXM1HRH3KCNH2KDM4EKMT2A | |
| SCHEMBL16594362 | 0.79 | TSHR (0.56) | FOXM1KDM4ESMN1; SMN2LTA4H | |
| SCHEMBL10274532 | 0.79 | HRH3 (0.56) | HRH3KCNH2CYP2C9KDM4ESMN1; SMN2 | |
| SCHEMBL14667598 | 0.79 | HRH3 (0.47) | FOXM1HRH3KCNH2CYP2C9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7253178-B2 | Carboxylic acids | EISAI CO., LTD. (JP) | 2007-08-07 | — | — | US | disclosed |
| US-7253178-B2 | Carboxylic acids | EISAI CO., LTD. (JP) | 2007-08-07 | — | — | US | disclosed |
| US-7253178-B2 | Carboxylic acids | EISAI CO., LTD. (JP) | 2007-08-07 | — | — | US | disclosed |
| US-20040116708-A1 | Insulin sensitizers; antidiabetic agents, antiinflammatory agents; inflammatory bowel disorders | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
| EP-1375484-A1 | CARBOXYLIC ACIDS | Eisai Co., Ltd. (JP) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | GPR119, IRS1, SLC5A1 | FOXM1 696/4885HRH3 955/4885KCNH2 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.